Drug Utilization Review Board

Size: px
Start display at page:

Download "Drug Utilization Review Board"

Transcription

1 DUR Members present DUR members absent MDCH/MMA/MPA present Steven Bernstein, M.D., Chair Carrie Germain, R. Ph, Vice Chair Bob DeYoung, PharmD James Forshee, M.D. Debera Eggleston, M.D. Sahar Swiden, PharmD Denise Dribben, M. D. Rajita Dnyate Helen Walley Donna Johnson, PharmD Giovannino Perri, M.D. Catherine Reid, M.D. Guests : Ryan Segroves Kevin Gallagh Christine Soltezli Jeff Paba Molly Wehrenberg David Stephens Paul Ford Gregg McDonald Kris Wenslovas Dave Skibicki Joseph Marchant David Larga Michelle Mischley Brenda FAbisch Jennifer McGovern Paige Nardf Catherine Reiland Shelly O Connor Dr. Bernstein called the meeting to order at 3:07 p.m. The minutes were reviewed and approved as written. The agenda was presented as follows: Topic: Department Business Issues 1. DUR Business : DUR Board composition was discussed. Members are to contact the Department with recommendations. Dr. Catherine Reid was introduced as the new Department physician in the Office of Medical Affairs. She will eventually assume responsibility of the DUR Board. 1

2 The United States Government Accountability Office (GAO) issued a report titled, FOSTER CHILDREN: HHS Guidance Could Help States Improve Oversight of Psychotropic Prescriptions, on December 1, 2011 ( Michigan was one of the states included in this report which looked at three quality indicators: 1. Children under age one on an antipsychotic medication 2. Polypharmacy, and 3. Use of mediations at doses other than the FDA approved maximum dose. The report recommends that a practice and prescribing guideline be adopted or endorsed by the federal government in oversight of the care of foster care children. The Board encouraged editing at point of sale to prevent payment for mediations which fall outside best practices. The Department reminded the Board of the contraints that Michigan the Public Acts 248 and 250 of 2004 pose in managing this drug class. After the report was published the Department ran more current data to identify patients on antipsychotics under the age of one. There was one case. In follow up with the pharmacy that billed this prescription, it was discovered to be a billing error. The script was written for the mother of the beneficiary and needed to be billed under the mother s ID #. Action: Dr. Bernstein asked that Magellan Medicaid Administration (MMA) supply a comparison of other clients handling of the behavioral health drug classes, especially the atypical antipsychotics. The Board asked this information be disseminated prior to the next meeting. The meetings for next year were confirmed for the second Tuesday of the month in which we meet. The dates will be March 13, June 12, September 11 and December 11, Meeting dates will be posted to the website ( ). 2

3 1. Eligibility Numbers: Eligibility numbers were presented and reviewed. The numbers remain stable at this time. There was discussion regarding the Patient Protection and Affordable Care Act (PPACA) will have on the numbers with Medicaid expansion taking effect January 1, P & T Update: The drug classes of Analgesics and Central Nervous System will be discussed at the evening meeting with little changes along with the introduction of the new members and chair of the P & T committee. Ad Hoc Reports for the P & T committee were then discussed. a. Persistence of secretin mimetic utilization- The data was presented and discussed. There appeared to be limited persistence; however, continuous eligibility needs to be confirmed in this analysis. b. Secretin mimetic and other DM medication utilization- The data was reviewed. Dr. Bernstein indicated the VA requires Secretin mimetics to be add on therapy following initiation of other agents first. c. Adult Growth hormone utilization - The utilization data and FDA indications for each growth hormone (GH) were reviewed. The pediatric endocrinologists in the state meet routinely to discuss care of patients. They have issued a position paper regarding transitioning of patients into adulthood on GH. This document, which was prepared for Children s Special Health Care Services, was provided to the Board. In review of the 11 adult individuals using GH and their diagnoses, it appears the prescribing of GH in the adult population is appropriate based in paid claims. d. Biosimilarity of Growth Hormones-The Board supported the Department s interest in developing preferred agents in this drug class. Action: The Department will further analyze persistence for the secretin memetics. 3. Follow up for DUR Board a. Concurrent Use of 2 or more atypical antispychotics: Upon review of the data, the Board recommended a retro DUR letter be developed for mailing to 3

4 prescribers on this topic. The Pharmacists that review the patient detail reports should look for continuous enrollment of the beneficiary and at least two fills of the two different antipychotics before a letter is sent. The Board asked that when the pharmacists review profiles and decide against a letter being sent that an explanation be provided as well indicate why a letter was sent. The Board was interested in the number of cases when the same prescriber wrote two different antipsychotics as opposed to when there were 2 different prescribers. b. Concurrent Use of 2 or more SSRIs: Review of the data led the Board to recommend this as a possible future retro DUR letter. Many of the pharmacist review issues noted for the concurrent use of atypical antipsychotics apply to this topic as well. Dr. Forshee mentioned age edits would be helpful in prescribing of behavioral health medications to beneficiaries. Action: The Department will indicate the reason letters are sent or not sent in future retro DUR analysis. 4. Brand /Generic metrics: Presented and Reviewed. No new discussion. 5. Retro DUR Reports : Topics presented are as follows: a. Triptans without controllers b. Underutilization of beta-blockers in post-mi patients- Volume is quite low and probably does not warrant repeating. c. Low-dose Seroquel. Topic selections for future retro DUR letters include: ADHD medication initiation with appropriate follow up as set forth in HEDIS Polypharmacy of five or more mental health drugs broken out by age (<1, 1-5, 6-12, 13). The Board is interested in knowing why a beneficiary under one year of age, if one is found, would hit on this indicator before the next Board meeting 6. Academic Detailing: The current academic detailing project is educating prescribers of Suboxone about the Michigan Automated Prescribing System (MAPS). It appears approximately 200 prescribers are not registered with MAPS. This is the group with which the 4

5 detailers will start. Webinar training by Mike Wissel from LARA has been completed for the pharmacist detailers. A feedback form will be provided for the prescribers at each visit. Board members emphasized the need to determine if the deficit is related to knowledge, attitude, or behavior. 7. Public comment: There was discussion of the appropriateness of secretin mimetic prescribing and guidelines. The meeting was adjourned at 4:50 pm by Dr. Bernstein. 5

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

Monitoring Psychotropic Use Among Foster Children EMPAA

Monitoring Psychotropic Use Among Foster Children EMPAA State Plans for Monitoring Psychotropic Use Among Foster Children EMPAA October 30, 2012 Child and Family Services Improvement and Innovation Act of 2011 Required Components of Psychotropic Oversight and

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Date: July 16, 2015 Time: 9am-1:30pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting March 2015 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Charles Caley Pharm.D. BCPP, Ram Illindala, MD, Carol

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: October 16, 2014 Time: 9am-2pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting September 2018 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke, R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Ram Illindala, MD, Dennis Chapron, Pharm.D. Ex Officio

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting September 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram

More information

Facilitating Cross-System Data Sharing for Psychotropic Medication Oversight and Monitoring

Facilitating Cross-System Data Sharing for Psychotropic Medication Oversight and Monitoring Improving the quality and cost-effectiveness of publicly financed health care Facilitating Cross-System Data Sharing for Psychotropic Medication Oversight and Monitoring Psychotropic Medication Use Among

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting December 2012 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Bhupesh Mangla, M.D., Charles Caley, Pharm.D., Ram Illindala, M.D., Richard

More information

Drug Utilization Review Board Minutes Draft

Drug Utilization Review Board Minutes Draft Drug Utilization Review Board Minutes Draft Name of Meeting: Drug Utilization Review Board Date of Meeting: August 10, 2017 Length of Meeting: 2 hours Location of Meeting: DMAS Board Room 13 th Floor Members

More information

Curbing Prescription Drug Abuse in Medicaid

Curbing Prescription Drug Abuse in Medicaid Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance

More information

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D. Date: February 16, 2017 Time: 9am-12:15pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Perry Brown, M.D. Committee Member

More information

ATTENDANCE PRESENT ABSENT EXCUSED Robert Weiss, M.D., Cardiologist, Chair X Amy Enos, Pharm. D. Waltz LTC Pharmacy

ATTENDANCE PRESENT ABSENT EXCUSED Robert Weiss, M.D., Cardiologist, Chair X Amy Enos, Pharm. D. Waltz LTC Pharmacy TO: Maine Drug Utilization Review Board DATE: April 10, 2014 RE: Maine DUR Board Meeting minutes from April 8, 2014 ATTENDANCE PRESENT ABSENT ECUSED Robert Weiss, M.D., Cardiologist, Chair Amy Enos, Pharm.

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting March 2018 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke, R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Ram Illindala, MD, Dennis Chapron, PharmD., Carol Drufva,

More information

Disclosure Statement. Learning Objectives. Background. Background 4/26/2016

Disclosure Statement. Learning Objectives. Background. Background 4/26/2016 Disclosure Statement Implementation of Education plus Provider- Specific Prescribing Reports and the Effects on Antipsychotic Polypharmacy in Children and Adolescents with Mental Illness in an Outpatient

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting June 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram Illindala,

More information

The Pediatric Behavioral Health Medication Initiative September 2016

The Pediatric Behavioral Health Medication Initiative September 2016 The Pediatric Behavioral Health Medication Initiative Neha Kashalikar, PharmD Clinical Consultant Pharmacist UMass Medical School Clinical Pharmacy Services Background Several studies investigated trends

More information

STATE OF NEW JERSEY OFFICE OF THE STATE COMPTROLLER MEDICAID FRAUD DIVISION

STATE OF NEW JERSEY OFFICE OF THE STATE COMPTROLLER MEDICAID FRAUD DIVISION STATE OF NEW JERSEY OFFICE OF THE STATE COMPTROLLER MEDICAID FRAUD DIVISION COMPLIANCE AUDIT REVIEW OF SUBOXONE FINAL AUDIT REPORT A. Matthew Boxer September 25, 2013 COMPTROLLER Executive Summary As part

More information

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Texas Vendor Drug Program Specialty Drug List Process. February 2019 Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed

More information

Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care

Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care Appendices Appendix A Psych Meds Data Indicators by State The data elements being collected by the

More information

Massachusetts Department of Developmental Services. Medication Review

Massachusetts Department of Developmental Services. Medication Review Massachusetts Department of Developmental Services Medication Review NASDDDS Reinventing Quality August 7, 2012 Alixe Bonardi 1, Gail Grossman 2 Emily Lauer 1 1 University of Massachusetts Medical School

More information

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee December 13, 2016 Minutes Attendees: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr.

More information

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010 Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010 Physician-Administered Drugs Physician-administered drugs are drugs, other than vaccines,

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D. Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member

More information

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment

More information

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting

Connecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting March 2011 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Richard Gannon, Pharm.D., Bhupesh Mangla, M.D., Ram Illindala, M.D., Charles Caley,

More information

Disclosures. Book Royalties Lippincott, Williams & Wilkins

Disclosures. Book Royalties Lippincott, Williams & Wilkins Update on OPAL-K DATE: October 20, 2016 PRESENTED BY: Keith Cheng, M.D., Clinical Associate Professor Department of Psychiatry, Oregon Health & Science University Disclosures Book Royalties Lippincott,

More information

Massachusetts Department of Developmental Services Medication Review

Massachusetts Department of Developmental Services Medication Review University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 8-7-2012 Massachusetts Department of Developmental Services Medication Review Alexandra

More information

The Louis de la Parte Florida Mental Health Institute

The Louis de la Parte Florida Mental Health Institute Data Brief December 2003 Mary Rose Murrin, M.A. Kelley Dhont, M.S. David Thornton, M.A. The Louis de la Parte Florida Mental Health Institute Children s Psychotropic Medication Use by Age and Diagnostic

More information

AMCP Webinar Series. Exchanges and Qualified Health Plans: How your voice can shape the future of quality reporting 14 January 2014.

AMCP Webinar Series. Exchanges and Qualified Health Plans: How your voice can shape the future of quality reporting 14 January 2014. AMCP Webinar Series Exchanges and Qualified Health Plans: How your voice can shape the future of quality reporting 14 January 2014 Speaker Mitzi Wasik, Pharm.D., BCPS Director, Pharmacy Medicare Programs

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short

More information

Drug Utilization Review Board Minutes Draft

Drug Utilization Review Board Minutes Draft Drug Utilization Review Board Minutes Draft Name of Meeting: Drug Utilization Review Board Date of Meeting: March 22, 2018 Length of Meeting: 2 hours and 12 minutes Location of Meeting: DMAS Board Room

More information

Pharmaceutical Management Medicaid 2019

Pharmaceutical Management Medicaid 2019 Pharmaceutical Management Medicaid 2019 Toll-free Contact Number: (888) 327-0671 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical Management promotes the use of the most clinically appropriate,

More information

HOSPICE INFORMATION FOR MEDICARE PART D PLANS

HOSPICE INFORMATION FOR MEDICARE PART D PLANS HOSPICE INFORMATION FOR MEDICARE PART D PLANS SECTION I -HOSPICE INFORMATION TO OVERRIDE AN HOSPICE A3 REJECT OR TO UPDATE HOSPICE STATUS A. Purpose of the form (please check all appropriate boxes) : Admission

More information

April 21, 2010 DURB Meeting Summary

April 21, 2010 DURB Meeting Summary Roll Call Present: Dr. Swee, Ms. Olson, Ms. Martinez- Rodriguez, Dr. Barberio, Dr. Gooen, Dr. Gochfeld, Dr. Lichtbroun Absent: Dr. Moore, Dr. Marcus, Mr. Schafer, Dr. Moynihan, Review of Minutes Pages

More information

NAQC Conference 2017 Lunch Plenary

NAQC Conference 2017 Lunch Plenary NAQC Conference 2017 Lunch Plenary State Innovations: Enhancing Quitline Services for Medicaid Smokers Karen Brown, MPH Paula Celestino, MPH Tasha Moses, MPA Moderator: Linda Bailey, JD, MHS Tuesday, March

More information

TO: Maine Drug Utilization Review Board FROM: Sally Griffith-Onnen DATE: January RE: Maine DUR Board meeting minutes from January 12, 2010

TO: Maine Drug Utilization Review Board FROM: Sally Griffith-Onnen DATE: January RE: Maine DUR Board meeting minutes from January 12, 2010 TO: Maine Drug Utilization Review Board FROM: Sally Griffith-Onnen DATE: January 13 2010 RE: Maine DUR Board meeting minutes from January 12, 2010 Department of Health and Human Services MaineCare Services

More information

Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star

Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star HEALTH ALLIANCE PLAN Presented by Vanita K. Pindolia, Pharm.D. VP, Ambulatory Clinical Pharmacy Programs_PCM Medicare 5-Star Rating

More information

Title: Antipsychotic Use in Persons with Dementia CMS ID: ARCO3 NQF #: N/A

Title: Antipsychotic Use in Persons with Dementia CMS ID: ARCO3 NQF #: N/A Source(s) Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p. Measure Domain Clinical Quality Measures:

More information

General Providers. Tamper-Resistant Prescription Requirements

General Providers. Tamper-Resistant Prescription Requirements September 2008 Provider Bulletin Number 8138 General Providers Tamper-Resistant Prescription Requirements Effective with processing dates on and after October 1, 2008, written prescriptions for Kansas

More information

Comparison of two methods of introduction to an academic detailing program: ADHD treatment among pediatric Medicaid patients

Comparison of two methods of introduction to an academic detailing program: ADHD treatment among pediatric Medicaid patients Comparison of two methods of introduction to an academic detailing program: ADHD treatment among pediatric Medicaid patients The 4 th International Conference on Academic Detailing Jacki Travers, Pharm.D.

More information

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Attendees: Commission Members Bruce Alexander, R.Ph., Pharm.D., BCPP; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,

More information

Sample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits

Sample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits Technical Assistance Tool October 2017 Sample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits C ross-agency Medicaid-Public Health teams interested

More information

EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC

EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC RAMI R KHOURY, MD, FACEP ASSISTANT MEDICAL D IRECTOR EMERGENCY C A R E ALLEGIANCE HEALTH ADVERTISING AT ITS BEST! OVERDOSE

More information

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.

Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. COMMUNITY PHARMACY V1.1 MANDATORY S Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. # NAME DESCRIPTION NUMERATOR DENOMINATOR

More information

June 4, Via Electronic Transmission

June 4, Via Electronic Transmission June 4, 2008 Via Electronic Transmission Dr. Drew Gilpin Faust President Harvard University Massachusetts Hall Cambridge, MA 02138 Dr. Peter L. Slavin President Massachusetts General Hospital (Partners

More information

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE TO: FROM: SUBJECT: All Part D Sponsors Amy Larrick

More information

Medicaid Perspective

Medicaid Perspective Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:

More information

Hedis Behavioral Health Measures

Hedis Behavioral Health Measures Hedis Behavioral Health Measures Generating better health outcomes and improving HEDIS scores is a positive outcome for everyone. Magellan Complete Care is offering support by providing the details of

More information

October 2015 news bulletin

October 2015 news bulletin October 2015 news bulletin Claims tip of the month billing medical injectables For single dose vials, providers should bill Amerigroup Washington, Inc. for the total amount of the drug contained in the

More information

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy

More information

Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the

Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the Maryland Medicaid Pharmacy Program & News ViewsNovember 2013 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy The Antipsychotic Peer Review Program is Expanding!

More information

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014

Medi Cal Managed Care. Melissa Lamer, PharmD, BCPP July 31 st, 2014 Pharmacy Benefit Carve Outs in Medi Cal Managed Care Melissa Lamer, PharmD, BCPP July 31 st, 2014 2 The Behavioral Health Carve Out Services Carved Out to the County Starting 1/1/2014 Medi Cal plans now

More information

TennCare Drug Utilization Review (DUR) Board Minutes

TennCare Drug Utilization Review (DUR) Board Minutes State of Tennessee Department of Finance and Administration Bureau of TennCare 310 Great Circle Road Nashville, TN 37228 TennCare Drug Utilization Review (DUR) Board Minutes September 11, 2012 In attendance:

More information

Drug Use Evaluation: Low Dose Quetiapine

Drug Use Evaluation: Low Dose Quetiapine Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID BACKGROUND Cytokine and cell-adhesion molecule (CAM) antagonists have a major role in the treatment of chronic inflammatory diseases such

More information

Risk Evaluation And Mitigation Strategies:

Risk Evaluation And Mitigation Strategies: Risk Evaluation And Mitigation Strategies: The Experts Answer Questions from Health-System Pharmacists A midday symposium about the risk evaluation and mitigation strategies (REMS) required by the Food

More information

Executive Summary. Classes Under Review: Analysis:

Executive Summary. Classes Under Review: Analysis: Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation

More information

Follow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites)

Follow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites) 15 January 2015 1 Follow-up to Previous Reviews Foster Children Prescribers (Nurse Practitioner Practice Sites) 2 Foster Children Prescribers (Nurse Practitioner Practice Sites) 3 Ongoing Reviews Buprenorphine

More information

Part D Benefits & Clinical Research Trials: What's Covered

Part D Benefits & Clinical Research Trials: What's Covered Part D Benefits & Clinical Research Trials: What's Covered Presented by: Ryan Meade, JD Meade & Roach, LLP 312.498.7004 RMeade@MeadeRoach.com Health Care Compliance Association December 12, 2005 Baltimore,

More information

WY P&T Committee Meeting Minutes Thursday, May 19, 2011 Cheyenne, WY 9 a.m. 3 p.m.

WY P&T Committee Meeting Minutes Thursday, May 19, 2011 Cheyenne, WY 9 a.m. 3 p.m. WY P&T Committee Meeting Minutes Thursday, May 19, 2011 Cheyenne, WY 9 a.m. 3 p.m. Members present: Steen Goddik, Kurt Hopfensperger, Joe Horam, Scott Johnston, Richard Johnson, Maria Kidner, Robert Monger,

More information

EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC

EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC RAMI R KHOURY, MD, FACEP ASSISTANT MEDICAL DIRECTOR EMERGENCY CARE ALLEGIANCE HEALTH ADVERTISING AT ITS BEST! OVERDOSE

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Medicare Part D Overutilization Monitoring System

Medicare Part D Overutilization Monitoring System Medicare Part D Overutilization Monitoring System Lisa Thorpe, Division of Part D Policy Gary Wirth, Division of Clinical and Operational Performance Medicare Drug Benefit and C&D Data Group July 17, 2013

More information

Fall 2018 Research Training Program Agenda. S E S SI ON 1, Tuesday, S eptember 11, 2018

Fall 2018 Research Training Program Agenda. S E S SI ON 1, Tuesday, S eptember 11, 2018 S E S SI ON 1, Tuesday, S eptember 11, 2018 7:45 am 8:15 am Sign-In - Refreshments provided, course materials distributed 8 : 1 5 a m - 8 : 2 5 a m Introduction Welcome and overview of the six session

More information

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences

More information

Opioid Response Package Awaits President s Signature Trinity Tomsic

Opioid Response Package Awaits President s Signature Trinity Tomsic Issue Brief 18-38, October 19, 2018 Opioid Response Package Awaits President s Signature Trinity Tomsic 202-624-8577 ttomsic@ffis.org Summary Congress passed the SUPPORT for Patients and Communities Act

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: April 14, 2016 Time: 9am-12:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

Prevention Committee Meeting United Way Ansin Building, 3250 SW 3 rd Avenue, Conference Room A, Miami, FL 33129

Prevention Committee Meeting United Way Ansin Building, 3250 SW 3 rd Avenue, Conference Room A, Miami, FL 33129 Prevention Committee Meeting United Way Ansin Building, 3250 SW 3 rd Avenue, Conference Room A, Miami, FL 33129 Approved on March 24, 2016 # Members Present Absent Guests 1 Bannister, Christina X Barros,

More information

NPA SPRING POLICY FORUM. April 1 2, H The Mayflower Hotel H Washington, DC CONFERENCE PROGRAM PACE NATIONAL ASSOCIATION

NPA SPRING POLICY FORUM. April 1 2, H The Mayflower Hotel H Washington, DC CONFERENCE PROGRAM PACE NATIONAL ASSOCIATION NPA SPRING POLICY FORUM April 1 2, 2019 H The Mayflower Hotel H Washington, DC CONFERENCE PROGRAM PACE NATIONAL ASSOCIATION About the Forum The National PACE Association (NPA) invites you to join us for

More information

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage

More information

Please submit all questions concerning webinar content through the Q&A panel. Reminder:

Please submit all questions concerning webinar content through the Q&A panel. Reminder: NAACCR 2015-2016 Clinical Outcomes and Webinar Quality Series Improvement: Oncology Dashboard Drivers NAACCR Webinar Series 2016 2017 Lisa D. Landvogt, BA, CTR LLandvo1@hfhs.org Jocelyn Hoopes, MLIS, CTR,

More information

Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee

Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee June 14, 2016 Minutes Final Attendee: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr.

More information

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE BOARD OF PHYSICAL THERAPY GENERAL RULES

DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE BOARD OF PHYSICAL THERAPY GENERAL RULES DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE BOARD OF PHYSICAL THERAPY GENERAL RULES (By authority conferred on the director of the department of licensing and regulatory affairs by

More information

Improving Mental Health Care: A Case Study

Improving Mental Health Care: A Case Study Improving Mental Health Care: A Case Study Why Improve Mental Health Care? Because the prevalence and costs of mental health problems are increasing in America despite the high prescribing of psychotropic

More information

A COMPREHENSIVE APPROACH TO MANAGING DIABETES

A COMPREHENSIVE APPROACH TO MANAGING DIABETES A COMPREHENSIVE APPROACH TO MANAGING DIABETES Programs and services to help individuals avoid costly complications and improve outcomes 2 0 1 8 ENTER Supporting each member with targeted guidance and services.

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on: Statement Of The National Association of Chain Drug Stores For U.S. Senate Finance Committee Hearing on: 10:30 a.m. 215 Dirksen Senate Office Building National Association of Chain Drug Stores (NACDS)

More information

WY P&T Committee Meeting Minutes Thursday, November 8, 2018 Cheyenne, WY 10 a.m 1 p.m.

WY P&T Committee Meeting Minutes Thursday, November 8, 2018 Cheyenne, WY 10 a.m 1 p.m. WY P&T Committee Meeting Minutes Thursday, November 8, 2018 Cheyenne, WY 10 a.m 1 p.m. Members present: Hoo Fang Choo, Joseph Horam, Paul Johnson, Scott Johnston, Rhonda McLaughlin, Robert Monger, Chris

More information

Dr. Ariella Zbar, S. Laclé, Shana Calixte, JenniferAmyotte, Richard Waugh, Stephanie Kehoe, Catherine Watson, James Killeen

Dr. Ariella Zbar, S. Laclé, Shana Calixte, JenniferAmyotte, Richard Waugh, Stephanie Kehoe, Catherine Watson, James Killeen Community Drug Strategy for the City of Greater Sudbury Steering Committee Meeting 2018-02 Tuesday, March 20, 2018 10:30 AM-12:00 PM Withdrawal Management Services 336 Pine Street Present: Regrets: Guests:

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.

Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget. Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain

More information

Re: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments

Re: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments VIA Electronic Submission to http://www.regulations.gov September 29, 2009 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket

More information

The Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association

The Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association Development This activity was developed by the American Pharmacists

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

What Do IACP Members Think?

What Do IACP Members Think? What Do IACP Members Think? Results of a National Survey of Compounding Practitioners February 27, 2013 Final Summary Results What Do Compounders Think? National Survey of 2,857 pharmacists and technicians

More information

Mail Service Pharmacy

Mail Service Pharmacy Mail Service s At A Glance Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation.

More information

QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit

QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit QIOs: Partners for Quality Improvement Under the Medicare Drug Benefit Presentation to The 2 nd Annual National Medicare Prescription Drug Congress David Schulke Executive Vice President The American Health

More information

11/12/2015 THE LATEST ON THE 340B FRONT AGENDA MEGA GUIDANCE RELEASED. Mega Guidance released. Audit update from HRSA. Maintaining compliance

11/12/2015 THE LATEST ON THE 340B FRONT AGENDA MEGA GUIDANCE RELEASED. Mega Guidance released. Audit update from HRSA. Maintaining compliance November 19, 2015 Connie Ouellette, Principal Carole Barker, Senior Consultant THE LATEST ON THE 340B FRONT berrydunn.com AGENDA Mega Guidance released Audit update from HRSA Maintaining compliance Areas

More information

Jan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X

Jan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X Primary Prevention Breast Cancer Prevention Member: Mammography reminder letters to female members ages 51.5-74 who are overdue to get a mammogram Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Providers:

More information

Mary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified

Mary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified Mary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified Endocrinology Coder) Mary Ann Hodorowicz, RDN, MBA, CDE, CEC, is a licensed registered dietitian and certified diabetes educator and earned her MBA with

More information

June 23, 2010 DURB Meeting Summary

June 23, 2010 DURB Meeting Summary Roll Call Present: Dr. Swee, Ms. Olson, Ms. Martinez- Rodriguez, Dr. Barberio, Dr. Gooen, Dr. Gochfeld, Dr. Lichtbroun, Dr. Marcus Absent: Dr. Moore, Mr. Schafer, Dr. Moynihan, Review of Minutes Pages

More information

ONTARIO NIHB Regional Dental Benefit Grid Denturists

ONTARIO NIHB Regional Dental Benefit Grid Denturists Denturists Effective Date April 1, 2019 The coverage of dental services provided through the NIHB Program will be reimbursed in accordance with the terms and conditions of the Program. Predetermination

More information

THE LATEST ON THE 340B FRONT

THE LATEST ON THE 340B FRONT September 1, 2015 Connie Ouellette, Principal Carole Barker, Senior Consultant THE LATEST ON THE 340B FRONT berrydunn.com AGENDA Mega Guidance released! Audit update from HRSA Maintaining compliance Areas

More information

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES COUNTY OF MARIN Larry Meredith, Ph.D., Director DIVISION OF PUBLIC HEALTH COMMUNITY HEALTH & PREVENTION SERVICES Marin HIV/AIDS Care Council Meeting 899 NORTHGATE

More information

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction

More information

2015 Annual Convention

2015 Annual Convention 2015 Annual Convention Date: Tuesday, October 13, 2015 Time: 8:00 am 9:30 am Location: Gaylord National Harbor Resort and Convention Center, National Harbor 2 Title: Activity Type: Speaker: Benefit from

More information

SASKATCHEWAN NIHB Regional Dental Benefit Grid Denturists

SASKATCHEWAN NIHB Regional Dental Benefit Grid Denturists Denturists Effective Date February 1, 2019 The coverage of dental services provided through the NIHB Program will be reimbursed in accordance with the terms and conditions of the Program. Predetermination

More information

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017 Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information